PUBLISHER: GlobalData | PRODUCT CODE: 1410833
PUBLISHER: GlobalData | PRODUCT CODE: 1410833
Human Immunodeficiency Virus (HIV) Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on HIV Tests market for the year 2020 and beyond. HIV is an ongoing, global public health issue that remains a major priority for most governments. HIV tests are performed for two purposes:
i) screening and diagnosis; or
ii) ii) monitoring of HIV-positive patients, particularly those undergoing antiretroviral therapy (ART).
Screening of pregnant women for HIV is standard of care in most countries and considered to be a cost-effective strategy for reducing the risk of transmission to the baby. Women are typically screened during their first trimester of pregnancy. For pregnant women at high-risk of acquiring HIV, testing is sometimes repeated at the beginning of the third trimester (28 weeks) or at the time of delivery.
The HIV diagnostic tests includes, HIV Point of care (POC) Tests, HIV EIA Tests, Multi-parameter HIV, Hepatitis B, and Hepatitis C NAATs and HIV Nucleic Acid Amplification Tests (NAATs). The HIV monitoring tests include NAAT for Viral Load and CD4 Count Tests.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed HIV Tests and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Abbott Laboratories, Becton Dickinson and Co, Danaher Corp, Bio-Rad Laboratories Inc, Hologic Inc, OraSure Technologies Inc, QuidelOrtho Corp, Oswaldo Cruz Foundation, Grifols SA, F. Hoffmann-La Roche Ltd, Siemens AG, Qiagen NV, Trinity Biotech Plc, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -
Not Applicable
Not Applicable
Not Applicable